Global trends and hotspots in research of paronychia: A bibliometric analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
ppublish
Résumé
Paronychia is a prevalent clinical disease profoundly affecting patients' quality of life. As ongoing evolution in modern living environments, factors contributing to paronychia are becoming increasingly diverse. Therefore, a further understanding about latest trend of paronychia is imperative and pressing. A systematic literature search was performed based on Web of Science Core Collection and Science Citation Index Expanded. The search parameters encompassed keywords associated with paronychia from 1980 to 2023, and rigorous data cleaning procedures were executed to maintain the analysis's relevance and dependability, supplemented by a thorough examination of abstracts and titles. Visibility analysis was conducted with Citespace and VOSviewer tools to explore the publication trends, collaborative networks, and impactful studies. A total of 595 articles were included in this study. The annual publication trends exhibited a significant increase since 1990, reached a peak of 41 articles in 2021. Collaborative relationships among countries demonstrated strong connections, with the United States leading in both publication volume, citation records and international cooperation. Keyword analysis indicated that in recent years, a substantial body of research has concentrated on paronychia issues caused by epidermal growth factor receptor inhibitors (EGFRI)-class drugs, such as Gefitinib, Erlotinib, and Afatinib, in the context of tumor treatment. In this area, most of the recent hotspots are not focused on the basic research about paronychia due to the basic research about traditional paronychia already reached a relative mature stage. However, with the widespread clinical application of EGFRI anticancer drugs, the incidence of drug-induced paronychia is inevitably on the rise. Therefore, with the expanding diversity in the etiology of paronychia, this area deserves a multiple discipline cooperation with a much wider international communication.
Sections du résumé
BACKGROUND
BACKGROUND
Paronychia is a prevalent clinical disease profoundly affecting patients' quality of life. As ongoing evolution in modern living environments, factors contributing to paronychia are becoming increasingly diverse. Therefore, a further understanding about latest trend of paronychia is imperative and pressing.
METHODS
METHODS
A systematic literature search was performed based on Web of Science Core Collection and Science Citation Index Expanded. The search parameters encompassed keywords associated with paronychia from 1980 to 2023, and rigorous data cleaning procedures were executed to maintain the analysis's relevance and dependability, supplemented by a thorough examination of abstracts and titles. Visibility analysis was conducted with Citespace and VOSviewer tools to explore the publication trends, collaborative networks, and impactful studies.
RESULTS
RESULTS
A total of 595 articles were included in this study. The annual publication trends exhibited a significant increase since 1990, reached a peak of 41 articles in 2021. Collaborative relationships among countries demonstrated strong connections, with the United States leading in both publication volume, citation records and international cooperation. Keyword analysis indicated that in recent years, a substantial body of research has concentrated on paronychia issues caused by epidermal growth factor receptor inhibitors (EGFRI)-class drugs, such as Gefitinib, Erlotinib, and Afatinib, in the context of tumor treatment.
CONCLUSION
CONCLUSIONS
In this area, most of the recent hotspots are not focused on the basic research about paronychia due to the basic research about traditional paronychia already reached a relative mature stage. However, with the widespread clinical application of EGFRI anticancer drugs, the incidence of drug-induced paronychia is inevitably on the rise. Therefore, with the expanding diversity in the etiology of paronychia, this area deserves a multiple discipline cooperation with a much wider international communication.
Identifiants
pubmed: 39331909
doi: 10.1097/MD.0000000000039838
pii: 00005792-202409270-00052
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e39838Subventions
Organisme : Capital’s Funds for Health Improvement and Research
ID : CFH 2022-4-2193
Informations de copyright
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Matter-Parrat V, Lazarus P, Goldammer F, et al. Homogenization of the management of acute paronychia with abscess formation within the context of an evaluation of professional practices. Orthop Traumatol Surg Res. 2021;107:102982.
Lomax A, Thornton J, Singh D. Toenail paronychia. Foot Ankle Surg. 2016;22:219–23.
Wong Y, Chen H, Lai C. Extensive pyomyositis secondary to paronychia-related MRSA infection: a case report. Medicine (Baltimore). 2022;101:e28431.
Relhan V, Goel K, Bansal S, Garg VK. Management of chronic paronychia. Indian J Dermatol. 2014;59:15–20.
Rocha BP, Verardino G, Leverone A, et al. Histopathological analysis of chronic paronychia. Int J Dermatol. 2023;62:514–7.
Chiriac A, Brzezinski P, Foia L, Marincu I. Chloronychia: green nail syndrome caused by Pseudomonas aeruginosa in elderly persons. Clin Interv Aging. 2015;10:265–7.
Leggit JC. Acute and chronic paronychia. Am Fam Physician. 2017;96:44–51.
Allouni A, Yousif A, Akhtar S. Chronic paronychia in a hairdresser. Occup Med (Lond). 2014;64:468–9.
Tosti A, Piraccini BM, D’Antuono A, Marzaduri S, Bettoli V. Paronychia associated with antiretroviral therapy. Br J Dermatol. 1999;140:1165–8.
Colson AE, Sax PE, Keller MJ, et al. Paronychia in association with indinavir treatment. Clin Infect Dis. 2001;32:140–3.
Kwon S, Choi J, Hong J, et al. Gefitinib-induced paronychia: response to autologous platelet-rich plasma. Arch Dermatol. 2012;148:1399–402.
Wang S, Yang C, Chiu H, et al. Skin manifestations of gefitinib and the association with survival of advanced non-small-cell lung cancer in Taiwan. Dermatol Sin. 2011;29:13–8.
Cheema PK, Thawer A, Leake J, Cheng SY, Khanna S, Charles Victor J. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. Support Care Cancer. 2019;27:1029–39.
Aria M, Cuccurullo C. bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr. 2017;11:959–75.
Van Eck N, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–38.
Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57:359–77.
Xiao N, Huang X, Zang W, et al. Health-related quality of life in patients with inborn errors of immunity: a bibliometric analysis. Front Immunol. 2024;15:1371124.
Wu Y, Zhou C, Hu C, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–22.
Soria J, Ohe Y, Vansteenkiste J, et al.; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25.
Shafritz AB, Coppage JM. Acute and chronic paronychia of the hand. J Am Acad Orthop Surg. 2014;22:165–74.
Amichai B, Shiri J. Fluconazole 50 mg/day therapy in the management of chronic paronychia. J Dermatol Treat. 1999;10:199–200.
Gorva AD, Mohil R, Srinivasan MS. Aggressive digital papillary adenocarcinoma presenting as a paronychia of the finger. J Hand Surg Br. 2005;30:534.
Durdu M, Ruocco V. Clinical and cytologic features of antibiotic-resistant acute paronychia. J Am Acad Dermatol. 2014;70:120–6.e1.
Kim US, Song KY, Youn JI, Chung JH. Paronychia–a manifestation of pemphigus vulgaris. Clin Exp Dermatol. 1996;21:315–7.
Goto H, Yoshikawa S, Mori K, et al. Effective treatments for paronychia caused by oncology pharmacotherapy. J Dermatol. 2016;43:670–3.
Alam M, Scher RK. Indinavir-related recurrent paronychia and ingrown toenails. Cutis. 1999;64:277–8.
Tosti A, Piraccini BM, Ghetti E, Colombo MD. Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol. 2002;47:73–6.
Tosti A, Guerra L, Morelli R, Bardazzi F, Fanti PA. Role of foods in the pathogenesis of chronic paronychia. J Am Acad Dermatol. 1992;27:706–10.
Tosti A, André M, Murrell DF. Nail involvement in autoimmune bullous disorders. Dermatol Clin. 2011;29:511–3, xi.
Tosti A, Piraccini BM. Treatment of common nail disorders. Dermatol Clin. 2000;18:339–48.
Lacouture ME, Anadkat MJ, Bensadoun R, et al.; MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–95.
Lacouture ME, Schadendorf D, Chu C, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13:721–8.
Brook I. Paronychia: a mixed infection: microbiology and management. J Hand Surg Br. 1993;18:358–9.
Tomczak H, Dańczak-Pazdrowska A, Polańska A, et al. Microbiological analysis of acute infections of the nail fold on the basis of bait thread test. Postepy Dermatol Alergol. 2017;34:110–5.
Ritting AW, O’Malley MP, Rodner CM. Acute paronychia. J Hand Surg Am. 2012;37:1068–70; quiz page 1070.
Pang H, Lee JY, Tan AB. Pincer nails complicated by distal phalangeal osteomyelitis. J Plast Reconstr Aesthet Surg. 2009;62:254–7.
Jebson PJ. Infections of the fingertip. Paronychias and felons. Hand Clin. 1998;14:547–55, viii.
Anakwenze OA, Milby AH, Gans I, Stern JJ, Levin SL, Wapner KL. Foot and ankle infections: diagnosis and management. J Am Acad Orthop Surg. 2012;20:684–93.
El-Komy M, Samir N. 1064 Nd: YAG laser for the treatment of chronic paronychia: a pilot study. Laser Med Sci. 2015;30:1623–6.
Liu Y, Lu W, Zhang Z, Wan H, Wang K, Ding X. A study on the efficacy of Ω toenail correction treating paronychia. J Foot Ankle Surg. 2023;62:939–42.
Masago K, Irie K, Fujita S, et al. Relationship between paronychia and drug concentrations of epidermal growth factor receptor tyrosine kinase inhibitors. Oncology (Huntingt). 2018;95:251–6.
Wu Y, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2013;24:993–9.